FATE earnings date and last-quarter result: last quarter in line, P/E -2.37. Updated 2026-07-23.
Fate Therapeutics (FATE) Research Hub
Fate Therapeutics (FATE) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 2.06 USD (-2.37%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.37, market cap 0.30B. This hub links to the full technical, earnings and options research available for FATE.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.06 USD (-2.37%) |
| 52-week range | 1.76 USD – 3.23 USD |
| Trend regime | Range |
| 14-day RSI | 38.1 (Bearish) |
| Trailing P/E | -2.37 |
| Market cap | 0.30B |
| Dividend yield | 0.00% |
Available research for FATE
Covered Call on FATE: how it works, illustrative setup around the real 2.06 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on FATE: how it works, illustrative setup around the real 2.06 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on FATE: how it works, illustrative setup around the real 2.06 USD price, max profit/loss, breakeven and when to use it. Educational.
FATE technical analysis: range, last 2.06 USD, RSI 38.1, 52w range 1.76 USD–3.23 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is FATE in?
Fate Therapeutics (FATE) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is FATE in an uptrend or downtrend?
As of 2026-10-26, FATE is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is FATE's trailing P/E ratio?
FATE's trailing P/E is -2.37, with a market cap of 0.30B. See the earnings research page for full valuation detail.